Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

This study has been completed.
Sponsor:
Collaborator:
Cellestis
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier:
NCT00168259
First received: September 13, 2005
Last updated: January 19, 2012
Last verified: January 2012
  Purpose

The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.


Condition
HIV Infection
CMV Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

Resource links provided by NLM:


Further study details as provided by The Alfred:

Biospecimen Retention:   Samples With DNA

Plasma, and DNA


Enrollment: 20
Study Start Date: December 2004
Study Completion Date: December 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HIV infected patients with past CMV infection initiating antiretroviral therapy

Criteria

Inclusion Criteria:

  1. HIV positive with history of documented HCV infection
  2. Over 18 years old
  3. HIV positive
  4. Antiretroviral naive, starting on antiretroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168259

Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
Cellestis
Investigators
Principal Investigator: Sharon Lewin, Professor The Alfred
  More Information

No publications provided

Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier: NCT00168259     History of Changes
Other Study ID Numbers: 185/04
Study First Received: September 13, 2005
Last Updated: January 19, 2012
Health Authority: Australia: National Health and Medical Research Council

Keywords provided by The Alfred:
Treatment Naive
HIV

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
Communicable Diseases
Cytomegalovirus Infections
HIV Infections
HIV Seropositivity
Infection
DNA Virus Infections
Herpesviridae Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interferon-gamma
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014